J Uriach (Barcelona, Spain) plans to improve its current developmental focus on inflammatory diseases through the deployment of the ActivityBase software
IDBS reports the latest implementation of its flagship product, ActivityBase.
J Uriach (Barcelona, Spain) plans to improve its current developmental focus on inflammatory diseases through the deployment of the ActivityBase software.
The company's 165-year heritage has resulted in many successful products, including the drug Triflusal (Disgren), currently one of the most prescribed antithrombotic agents in Spain.
Elena Carceller, head of medicinal chemistry for Uriach, said: "Our company has grown significantly during its long and prestigious history.
"This growth has presented us with new challenges regarding the day-to-day management of results.
"We needed a system that was scalable to our needs, but also one which was proven within the industry - which is why we chose IDBS".
IDBS first began discussing Uriach's requirements in 2003, when a clear requirement for one integrated platform to handle the biological, chemical and statistical data generated by the laboratory was established.
IDBS consultants determined how current information could be ported to the new ActivityBase environment, and how the new architecture could be applied to the current Uriach workflow.
This consultative approach prompted Robert Soliva, project manager for Uriach, to comment: "Rather than simply sell us a product, we were impressed with the professional approach IDBS adopted to ensure we had a system that was precisely suited to our requirements".
Neil Kipling, founder, chairman and CEO of IDBS said: "we have remained at the forefront of drug discovery data management for well over a decade now.
"It is deeply gratifying to know that major pharmaceutical companies continue to recognise the value our products deliver.
"IDBS views Spain as a significant emerging market for both biotech and pharmaceutical companies, and takes great pride in serving such a high percentage of those companies."
